Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
复制标题
DOI：
10.1038/nm1698
复制
发表时间：
2008-01-01
期刊：
影响因子：
82.9
通讯作者：
Burton, Dennis R.
中科院分区：
文献类型：
--
作者：
Law, Mansun;Maruyama, Toshiaki;Burton, Dennis R.
丙型肝炎病毒（HCV）免疫治疗或疫苗设计的一个主要问题是病毒的极端可变性。我们在人肝嵌合小鼠模型中鉴定出了人单克隆抗体（mab），它可以中和遗传多样性的HCV分离物，并保护人类免受异源HCV准种的攻击。结果表明，广泛中和的丙型肝炎病毒抗体可以预防异源病毒感染，并提示丙型肝炎病毒的预防性疫苗是可以实现的。
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.